Dr. Henrik Hagberg: delivering twins is stressful but it’s very rewarding
Editor’s note
The 7th Shanghai and the 3rd Asia Neonatal Forum was held on June 13–16, 2019 in Shanghai, China. This meeting is organized by Children’s Hospital of Fudan University, National Children’s Medical Center (China), Key Laboratory of Neonatal Diseases of National Health Commission (China), University of Gothenburg (Sweden), Canadian Neonatal Network (Canada) and Third Affiliated Hospital of Zhengzhou University (China). The AME editorial team was with great honor to invite Dr. Henrik Hagberg to conduct a brief interview during the meeting (Figures 1,2).
Expert introduction
Henrik Hagberg, MD, PhD.
Center of Perinatal Medicine and Health, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sweden.
Dr. Henrik Hagberg is a Swedish physician. His research focuses on experimental brain research, perinatal medicine and obstetrics. He is currently the head of the Centre of Perinatal Medicine and Health, Sahlgrenska Academy, Gothenburg, Sweden and affiliated Chair as professor in Fetal Medicine at the Centre for the Developing Brain at King's College London and is one of the world’s most highly cited researchers in the field of perinatal brain injury. According to Google Scholar, his work has been cited over 27,000 times in scientific literature, and he has an h-index of 100.
He has formerly been Professor of Obstetrics and Perinatal Medicine at Imperial College London and is currently Professor in the same field at Sahlgrenska Academy in Sweden. He has published over 400 articles.
Interview
Dr. Hagberg: This work started because of the study that was done in Parkinson Diseases which showed that GLP-1 (glucagon-like peptide-1) receptor analogues were neuroprotective. There was no study done in the perinatal brain, fetal brain or neonatal brain. It was interesting to see that it also protects the immature brain, that’s why we started out the study that we have done, showing its neuroprotective effect in three different models. We found that the GLP-1 analogues are highly protective in the neonatal brain. The good thing is that these drugs that have already been developed are given securely and safely to both children and adults, and it would be sufficient to give one or a few doses as these analogues have a duration of up to 1 week. We think it’s not just an opportunity. It’s also relatively low cost of maybe 10 dollars/infant. So one important advantage is that these analogues are acting on mechanisms critical in both the short term and in the long term perspective. So that is why we hope that maybe it’s possible to implement and repurpose these drugs from a treatment of type 2 diabetes to neuroprotection in the newborn.
Acknowledgments
Funding: None.
Footnote
Provenance and Peer Review: This article was commissioned by the editorial office, Pediatric Medicine. The article did not undergo external peer review.
Conflicts of Interest: The author has completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/pm.2019.09.01). The author has no conflicts of interest to declare.
Ethical Statement: The author is accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
(Science Editor: Seven Lin, PM, pm@amegroups.com)
Cite this article as: Lin S. Dr. Henrik Hagberg: delivering twins is stressful but it’s very rewarding. Pediatr Med 2019;2:56.